Cue Biopharma price to sales ratio CUE

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 3.6×
7-year median: 21.7×
Against its 7-year history: 7th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.6× to 197×
Peer median: 1.4×

Cue Biopharma's price to sales ratio is 3.6× as of Oct 23, 2026.

That is below its 7-year median of 21.7×, lower than on 93% of days in the last 7 years.

Over that time it ranged from 0.6× in Apr 2026 to 197× in May 2020.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.6×	0.6×	7.1×
2025	3.6×	3.0×	10.0×
2024	6.9×	3.1×	35.3×
2023	31.2×	9.1×	170×
2022	10.8×	6.0×	46.7×
2021	50.2×	50.2×	152×
2020	102×	81.8×	197×
2019	147×	72.9×	147×

Against its peers

Companies in Drug Manufacturers - General nearest Cue Biopharma's size, closest first, today.

Company	Price to sales ratio
CUECue Biopharma	3.6×
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ATNMActinium Pharmaceuticals	n/m
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

Where Cue Biopharma ranks

#68of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cue Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.